Literature DB >> 18384830

Multivalent binding of ricin to bovine serum albumin-based neoglycoconjugates.

Matthew C Blome1, Cara-Lynne Schengrund.   

Abstract

Ricin, a ribosome-inactivating protein from the plant Ricinus communis, is a heterodimeric protein. The A chain is a N-glycosidase and the B chain (RTB) is a lectin with two carbohydrate binding sites. RTB has been shown to bind asialofetuin with much greater affinity than it does galactose, supporting the hypothesis that it may exhibit multivalency. To test this, neoglycoconjugates were prepared and tested for their ability to function as ligands for ricin binding. Because the two carbohydrate binding sites on RTB are approximately 70A apart, bovine serum albumin (BSA) was used as the carbohydrate carrier. It was derivatized with either the oligosaccharide portion of asialo-GM1 or with lactose. These sugars were used because ricin was found to adhere more effectively to asialo-GM1 and LacCer immobilized on plastic than to the other glycosphingolipids tested. Results of binding studies done using surface plasmon resonance indicated that the RTB subunit of ricin exhibited a multivalent effect when it bound to the neoglycoconjugates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18384830     DOI: 10.1016/j.toxicon.2008.02.005

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  3 in total

Review 1.  Receptor mimicry as novel therapeutic treatment for biothreat agents.

Authors:  Richard J Thomas
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

2.  Surface plasmon resonance analysis of ricin binding to plasma membranes isolated from NIH 3T3 cells.

Authors:  Matthew C Blome; Kimberly A Petro; Cara-Lynne Schengrund
Journal:  Anal Biochem       Date:  2009-10-02       Impact factor: 3.365

Review 3.  Treatments for Pulmonary Ricin Intoxication: Current Aspects and Future Prospects.

Authors:  Yoav Gal; Ohad Mazor; Reut Falach; Anita Sapoznikov; Chanoch Kronman; Tamar Sabo
Journal:  Toxins (Basel)       Date:  2017-10-03       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.